Form 8-K - Current report:
SEC Accession No. 0001628280-25-031559
Filing Date
2025-06-16
Accepted
2025-06-16 16:06:35
Documents
14
Period of Report
2025-06-12
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K sgmo-20250612.htm   iXBRL 8-K 66661
2 EX-10.1 ex-101amendedandrestated20.htm EX-10.1 225617
6 GRAPHIC sangamoicons-06.jpg GRAPHIC 249916
  Complete submission text file 0001628280-25-031559.txt   724273

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT sgmo-20250612.xsd EX-101.SCH 1824
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT sgmo-20250612_lab.xml EX-101.LAB 21880
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT sgmo-20250612_pre.xml EX-101.PRE 12547
16 EXTRACTED XBRL INSTANCE DOCUMENT sgmo-20250612_htm.xml XML 2714
Mailing Address 501 CANAL BLVD. RICHMOND CA 94084
Business Address 501 CANAL BLVD. RICHMOND CA 94084 5109706000
SANGAMO THERAPEUTICS, INC (Filer) CIK: 0001001233 (see all company filings)

EIN.: 680359556 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-30171 | Film No.: 251050118
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)